BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 2:50:00 PM | Browse: 1037 | Download: 1042
Publication Name World Journal of Diabetes
Manuscript ID 3992
Country Switzerland
Received
2013-06-06 20:23
Peer-Review Started
2013-06-07 11:21
To Make the First Decision
2013-07-05 18:30
Return for Revision
2013-07-25 12:03
Revised
2013-08-12 20:45
Second Decision
2013-10-17 13:18
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-10-18 06:59
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-12-06 09:24
Publish the Manuscript Online
2013-12-20 16:49
ISSN 1948-9358 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Autobiography
Article Title Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan
Manuscript Source Invited Manuscript
All Author List Abhijit Shete, Aheson Shaikh, K Javeed Nayeem, Lily Rodrigues, Mohamed Sheikamunadeen Sadiq Ali, Parag Shah, Rajiv Khanna, Sarfaraj Majid, Sabeer A Rasheed, Shehla Shaikh and Tawfiqur Rahman
Funding Agency and Grant Number
Funding Agency Grant Number
Novartis Healthcare Private Limited, India
Corresponding Author Dr. Abhijit Shete, MD, Medical Department, Novartis Pharma AG, Core Technology Area, CH-4002, Basel, Switzerland. abhijit.shete@novartis.com
Key Words Dipeptidyl-peptidase 4 inhibitors; Fasting hypoglycemia; Sulfonylurea; Type 2 diabetes mellitus; Vildagliptin
Core Tip Management of glycemic control in diabetes patients fasting during Ramadan has been recognized as a critically important health challenge worldwide. India has the world’s second largest diabetes population and caters large Muslim community; however, there is limited data available exploring the effect of treatments in these fasting diabetes patients. This non-interventional, multicenter, double-arm study compared the effect of vildagliptin with sulfonylureas on hypoglycemic events, HbA1c, blood glucose levels, and response rate in 97 fasting diabetic patients during Ramadan in real-world setting. Vildagliptin appears to be an attractive treatment option for diabetes patients fasting during Ramadan.
Publish Date 2013-12-20 16:49
Citation Shete A, Shaikh A, Nayeem KJ, Rodrigues L, Ali MSS, Shah P, Khanna R, Majid S, Rasheed SA, Shaikh S, Rahman T. Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes 2013; 4(6): 358-364 Available from: URL: http://www.wjgnet.com/1948-9358/full/v4/i6/358.htm DOI: http://dx.doi.org/10.4239/wjd.v4.i6.358
URL http://www.wjgnet.com/1948-9358/full/v4/i6/358.htm
DOI http://dx.doi.org/10.4239/wjd.v4.i6.358
Full Article (PDF) WJD-4-358.pdf
Full Article (Word) WJD-4-358.doc
Manuscript File 3992-Review.docx
Answering Reviewers 3992-Answering reviewers.pdf
Copyright License Agreement 3992-Copyright assignment.pdf
Institutional Review Board Approval Form or Document Ethics Committee Approval Letter_Vildagliptin Versus Sulfonylurea in Indian Muslim Diabetes Patients Fasting During Ramadan.pdf
Peer-review Report 3992-Peer reviewer(s).pdf
Scientific Editor Work List 3992-Scientific editor work list.doc